Adaptive Biotechnologies Corporation
ADPTDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mosunetuzumab | Phase 2 | Diffuse Large B-Cell Lymphoma (DLBCL) | - | - |
Obinutuzumab | Phase 2 | Mantle Cell Lymphoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Adaptive Biotechnologies Corporation's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Adaptive Biotechnologies Corporation's (ADPT) pipeline across Phase 2. Its lead program is Mosunetuzumab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adaptive Biotechnologies Corporation's next FDA catalyst?→
Adaptive Biotechnologies Corporation's (ADPT) next tracked catalyst is a Earnings expected November 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ADPT biotech catalysts?→
Add ADPT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adaptive Biotechnologies Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.